Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
06/2000
06/15/2000WO2000034303A1 METHODS OF MODULATING TUMOR NECROSIS FACTOR α-INDUCED EXPRESSION OF CELL ADHESION MOLECULES
06/15/2000WO2000034298A1 Glyceryl nucleotides, method for the production thereof and their use
06/15/2000WO2000034295A2 Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
06/15/2000WO2000034281A1 Methotrexate derivatives
06/15/2000WO2000034248A1 New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
06/15/2000WO2000034246A1 Crystalline form of an octahydro-benzo(f)quinolin-3-one derivative
06/15/2000WO2000034245A2 Crystalline form of benzoquinoline-3-one derivatve as inhibitor of 5-alpha reductase
06/15/2000WO2000033917A1 Agents provided for treating tumors, based on liposomes, and containing tamoxifen
06/15/2000WO2000033888A2 Prodrug compounds and process for preparation thereof
06/15/2000WO2000033880A2 Conjugate used for enriching in neuronal cells
06/15/2000WO2000033878A2 Stabilization of macrolides
06/15/2000WO2000033876A1 Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors
06/15/2000WO2000033875A1 Chemotherapeutic composition and method
06/15/2000WO2000033874A2 Boron neutron capture therapy using pre-targeting methods
06/15/2000WO2000033871A2 Use of human prostate tumour cell lines in cancer treatment
06/15/2000WO2000033870A2 New cancer treatments
06/15/2000WO2000033869A2 Use of human prostrate cell lines in cancer treatment
06/15/2000WO2000033861A2 Pharmaceutical compositions containing protein-disulfide isomerases
06/15/2000WO2000033858A1 Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
06/15/2000WO2000033857A1 Cancer treatment composition and method using natural plant essential oils
06/15/2000WO2000033856A1 Cancer treatment composition and method using signal transduction modulators and natural plant essential oils
06/15/2000WO2000033844A1 Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants
06/15/2000WO2000033842A1 Myt1 kinase inhibitors
06/15/2000WO2000033841A1 Myt1 kinase inhibitors
06/15/2000WO2000033838A1 Vitronectin receptor antagonist
06/15/2000WO2000033837A2 Myt1 kinase inhibitors
06/15/2000WO2000033834A1 Use of isatin derivatives as ion channel activating agents
06/15/2000WO2000033833A1 Palladium-substituted bacteriochlorophyll derivatives and use thereof
06/15/2000WO2000033817A1 Phospholipid compositions
06/15/2000WO2000033814A2 Method for administering agents to the central nervous system
06/15/2000WO2000033809A1 Compositions containing a peptide and polylactic-glycolic acid suitable for preparing subcutaneous implants with an extended release period
06/15/2000WO2000015231A8 Adenosine a3 receptor modulators
06/15/2000WO2000010988A8 Water soluble analogs and prodrugs of paclitaxel
06/15/2000WO2000010600A3 Activation and protection of t-cells (cd4+ and cd8+) using an h¿2? receptor agonist and other t-cell activating agents
06/15/2000WO2000009107A3 Sulfonamides of n-containing heterocyclic thioesters for vision and memory disorders
06/15/2000WO2000005374A3 Molecules associated with cell proliferation
06/15/2000WO2000005369A3 Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
06/15/2000WO2000001821A3 Neurotransmission associated proteins
06/15/2000WO2000000469A3 Alkyl ketones as potent anti-cancer agents
06/15/2000WO1999066951A3 Use of bi-specific antibodies for pre-targeting diagnosis and therapy
06/15/2000WO1999066051A3 Nek-related and bub1-related protein kinases
06/15/2000WO1999061056A9 Methods and products for inducing mucosal immunity
06/15/2000WO1999061052A9 Oral immunization with papillomavirus virus-like particles
06/15/2000WO1999055858A3 Human nucleic acid sequences obtained from pancreas tumor tissue
06/15/2000WO1999047669A3 Human nucleic acid sequences from tissue of breast tumors
06/15/2000WO1999045016A3 Novel prodrugs for phosphorus-containing compounds
06/15/2000WO1999014328A3 Secreted and transmembrane polypeptides and nucleic acids encoding the same
06/15/2000WO1999002550A8 Ctl epitopes from ebv
06/15/2000DE19857009A1 Zubereitung mit verbesserter therapeutischer Breite, enthaltend Nukleotidsyntheseinhibitoren Preparation with improved therapeutic index containing nucleotide synthesis
06/15/2000DE19854628A1 Use of plant parts or extracts of Anacardiaceae for treatment or prevention of tumor diseases and as a prophylactic compound for the effects of gene toxins
06/15/2000CA2732620A1 Crystalline form of 40-o-(2-hydroxy-ethyl) rapamycin and process for preparation thereof
06/15/2000CA2678259A1 A recombinant vector expressing multiple costimulatory molecules and uses thereof
06/15/2000CA2651609A1 Crystalline form of 40-o- (2-hydroxy-ethyl) rapamycin and process for preparation thereof
06/15/2000CA2354766A1 Prodrug compounds and process for preparation thereof
06/15/2000CA2354266A1 Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors
06/15/2000CA2354188A1 Cancer cell vaccine
06/15/2000CA2354044A1 Protein transduction system and methods of use thereof
06/15/2000CA2354040A1 Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants
06/15/2000CA2354026A1 Beta-1,3-galactosyltransferase homologs
06/15/2000CA2354022A1 Crystalline form of benzoquinoline-3-one derivatve as inhibitor of 5-alpha reductase
06/15/2000CA2354021A1 Crystalline form of an octahydro-benzo(f)quinolin-3-one derivative
06/15/2000CA2353839A1 Methotrexate derivatives
06/15/2000CA2353797A1 Neuron-associated proteins
06/15/2000CA2353773A1 Cark protein and nucleic acid molecules and uses therefor
06/15/2000CA2353516A1 Cancer treatment composition and method using natural plant essential oils
06/15/2000CA2353476A1 Cancer treatment composition and method using signal transduction modulators and natural plant essential oils
06/15/2000CA2353475A1 Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
06/15/2000CA2353415A1 Vitronectin receptor antagonist
06/15/2000CA2352178A1 Phospholipid compositions
06/15/2000CA2351628A1 Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene
06/15/2000CA2351452A1 Methods and compositions useful for targeting activated vitronectin receptor .alpha.v.beta.3
06/15/2000CA2351060A1 Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation
06/15/2000CA2351059A1 Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
06/15/2000CA2349616A1 New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
06/15/2000CA2349404A1 Use of an immuno complex for the preparation of a therapeutic composition useful for transfecting a polynucleotide into macropinocyte cells
06/14/2000EP1008649A2 Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-b2(TGF-b2)
06/14/2000EP1008342A2 Pharmaceutically active compounds and liposomes, and methods of use thereof
06/14/2000EP1007717A2 Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
06/14/2000EP1007715A2 Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
06/14/2000EP1007714A1 Regulatory sequences capable of conferring expression of a heterologous dna sequence in endothelial cells in vivo and uses thereof
06/14/2000EP1007696A1 Il-13 receptor specific chimeric proteins and uses thereof
06/14/2000EP1007695A2 Rab proteins
06/14/2000EP1007693A1 Pak kinase genes and polypeptides and methods of use thereof
06/14/2000EP1007678A1 Kringle1
06/14/2000EP1007672A1 Intracellular glucocorticoid-induced leucine zippers modulators of apoptic cell death pathways
06/14/2000EP1007663A2 Human proteins
06/14/2000EP1007662A1 Method for induction of apoptotic cell death in malignant cells, through reduction of the rb to apoptosis inducing proteins ratio
06/14/2000EP1007658A2 Mdm2-specific antisense oligonucleotides
06/14/2000EP1007656A1 Modified protein kinase a-specific oligonucleotides and methods of their use
06/14/2000EP1007652A1 Transgenic animals with knocked-in vec receptor genes and uses thereof
06/14/2000EP1007650A1 Pca3, pca3 genes, and methods of use
06/14/2000EP1007563A1 Hm74a receptor
06/14/2000EP1007556A2 Troponin subunits and fragments useful as angiogenesis inhibitors
06/14/2000EP1007552A2 Diagnostics and therapy of epstein-barr virus in autoimmune disorders
06/14/2000EP1007551A2 Vaccine against hpv
06/14/2000EP1007545A2 Cyclopeptide derivatives as adhesion inhibitors
06/14/2000EP1007539A1 Secreted proteins and polynucleotides encoding them
06/14/2000EP1007535A1 Methods and compositions for diagnosis and treatment of breast cancer
06/14/2000EP1007534A1 Bh3 interacting domain death agonist
06/14/2000EP1007533A1 Bioconjugates and delivery of bioactive agents
1 ... 1902 1903 1904 1905 1906 1907 1908 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 ... 2211